Zhu Hong-Hu, Zhao Xiao-Su, Qin Ya-Zhen, Lai Yue-Yun, Jiang Hao
Department of Hematology, Peking University People's Hospital, Peking University Institute of Hematology, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing 100044, P.R. China.
Oncol Lett. 2016 Apr;11(4):2644-2650. doi: 10.3892/ol.2016.4260. Epub 2016 Feb 23.
The SET nuclear proto-oncogene (SET)-nucleoporin (NUP)214 fusion gene, which results from cryptic t(9;9)(q34;q34) or del(9)(q34.11q34.13), is a rare genetic event in hematological malignancies. The majority of patients carrying SET-NUP214 experience T-cell acute lymphoblastic leukemia (T-ALL), but rarely experience acute undifferentiated leukemia or acute myeloid leukemia. The current study presents the case of a 19-year-old male patient with B-cell ALL (B-ALL) carrying the SET-NUP214 fusion gene, in addition to an fms-related tyrosine kinase 3-internal tandem duplication mutation and a complex karyotype abnormality. The patient exhibited chemotherapy resistance. To the best of our knowledge, the present study is the first report of a case of B-ALL carrying the SET-NUP214 fusion gene, and provides a review of the literature.
SET核原癌基因(SET)-核孔蛋白(NUP)214融合基因由隐匿性t(9;9)(q34;q34)或del(9)(q34.11q34.13)产生,是血液系统恶性肿瘤中一种罕见的基因事件。大多数携带SET-NUP214的患者罹患T细胞急性淋巴细胞白血病(T-ALL),但很少罹患急性未分化白血病或急性髓系白血病。本研究报告了一例19岁男性B细胞急性淋巴细胞白血病(B-ALL)患者,其携带SET-NUP214融合基因,同时伴有fms相关酪氨酸激酶3内部串联重复突变和复杂的核型异常。该患者表现出化疗耐药性。据我们所知,本研究是首例关于携带SET-NUP214融合基因的B-ALL病例报告,并提供了文献综述。